ena-STUDY-Nutrition & Health-26-03-2018-11:57:16:494-892
The impact of AXOS intake in overweight individuals with metabolic syndrome.
A randomised crossover intervention using AXOS and polyunsaturated fatty acids (PUFA) on a cohort of subjects with overweight and metabolic syndrome (MetS) was completed. Only the first AXOS arm was assessed via shotgun metagenomics because no microbiota effects were anticipated in the PUFA arms, and the second AXOS arm showed carryover effects (metataxonomy approach). We showed, for the first time, that intake of ~10 g/day AXOS for 4 weeks drives significant changes in the structure of the human gut microbiota as a whole by concomitantly increasing the abundance of pivotal species for butyrate production. Our data also indicated that minor effects of AXOS intake had taken place at physiological and metabolic levels by inspection of several clinical parameters. As a consequence, we aimed to characterise a more detailed response of the human body to AXOS to gain insights into the less visible metabolic effects associated with its consumption. For this aim, we have analysed the group of responders to AXOS  consumption (to whom the gut microbiota was significantly altered).Registration: Registered under ClinicalTrials.gov Identifier no.NCT02215343
A randomised crossover intervention using AXOS and polyunsaturated fatty acids (PUFA) on a cohort of subjects with overweight and metabolic syndrome (MetS) was completed. Only the first AXOS arm was assessed via shotgun metagenomics because no microbiota effects were anticipated in the PUFA arms, and the second AXOS arm showed carryover effects (metataxonomy approach). We showed, for the first time, that intake of ~10 g/day AXOS for 4 weeks drives significant changes in the structure of the human gut microbiota as a whole by concomitantly increasing the abundance of pivotal species for butyrate production. Our data also indicated that minor effects of AXOS intake had taken place at physiological and metabolic levels by inspection of several clinical parameters. As a consequence, we aimed to characterise a more detailed response of the human body to AXOS to gain insights into the less visible metabolic effects associated with its consumption. For this aim, we have analysed the group of responders to AXOS  consumption (to whom the gut microbiota was significantly altered).Registration: Registered under ClinicalTrials.gov Identifier no.NCT02215343